Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 2NIH 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 1Genitourinary 1Endocrine 1CNS 1

Conditions

Recurrence 1Metastatic Neuroendocrine Prostate Cancer 1Medulloblastoma 1Ependymoma 1Advanced Solid Tumors 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Antiemetics × 1 year × Clear all
NCT06242691 2026-06-05

MK-1200-002

Merck Sharp & Dohme LLC

Phase 1/2 Completed
13 enrolled 21 charts
Other solid neoplasm

Advanced Solid Tumors

NCT06379217 2026-06-03

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Novartis

Phase 1 Active not recruiting
31 enrolled
EndocrineGenitourinary

Metastatic Neuroendocrine Prostate Cancer

NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 7 charts

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡